Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Steven M. Horwitz, Mehdi Hamadani, Michelle A. Fanale, Jay Feingold, Alexander I Spira, Paul A Fields, Tobias Menne, Anand Karnad, Alison J. Moskowitz, Catherine Hildyard, Shui He, Joseph Boni and Graham Collins | ||||||||||||
Title | Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma | ||||||||||||
|
|||||||||||||
URL | http://www.bloodjournal.org/content/130/Suppl_1/1510 | ||||||||||||
Abstract Text | Blood 2017 130(Suppl 1):1510 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Camidanlumab tesirine | Camidanlumab tesirine | 0 | 4 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Camidanlumab tesirine | ADCT-301|ADCT 301|ADCT301 | Camidanlumab tesirine (ADCT-301) is a human monoclonal antibody against CD25 linked to pyrrolobenzodiazepine dimer toxin, which may specifically target CD25-positive tumor cells (Blood 2017 130(Suppl 1):1510, PMID: 32521310, PMID: 32912922). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|